Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ziftomenib combinations in untreated NPM1-mutated or KMT2A-rearranged acute myeloid leukemia
jRCT2031260588Phase 3Recruiting
- Sponsor
- Kura Oncology
- Start
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ziftomenib in acute myeloid leukemia (AML) (4 arms), sponsored by Kura Oncology. Primary endpoints: Overall survival, Complete remission rate and 2 more. Started Nov 2026; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2031260588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260588.